We are monitoring the impact of COVID-19 on MEA Liquid Biopsy Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 894
Share on
Share on

Middle East & Africa Liquid Biopsy Market Research Report – Segmented By Cancer Type, Sample Type, Diagnostic Approach, End Users, Country (KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA) - Industry Analysis, Size, Share, Growth, Trends, Forecast (2021 to 2026)

Pulished: April, 2021
ID: 894
Pages: 145

MEA Liquid Biopsy Market Size (2021 to 2026)

The Middle East and Africa Liquid Biopsy Market size is expected to grow at a CAGR of 21.71% during the forecast period. As a result, the market size is predicted to value USD 421.95 million by 2026 from USD 157.99 million in 2021.

A liquid biopsy helps collect a wide range of information about cancer/tumors through a simple blood sample. For example, the procedure can help detect mutations in epidermal growth factor receptors in cancers. Liquid biopsies are also helpful in residual cancer detection, which can be performed with 5 milliliters of blood that would detect the present state of metastases in various tumors.

Liquid biopsy is a minimally invasive technique to analyze the non – solid biological tissues, mostly for the early detection of cancer. According to WHO, the number of cancer patients in the Middle East is increasing every year; according to WHO, the number will be double by 2030. Over 70% of deaths in the Middle East are due to cancer. According to WHO, 9 out of 22 countries in the Middle East do not have operational facilities for cancer treatment. Thus, the demand for liquid biopsy is increasing in this region as a liquid biopsy can be used to detect cancer. In addition, the liquid biopsy is less painful in comparison to traditional tissue biopsy. The government in this region is giving funds for the development of liquid biopsy to improve the health care service in this region. Inivata, a leading company in liquid biopsy, has signed a distribution agreement with IPS Genomix to provide InVisionFirst and InVisionSeq liquid biopsy tests in the Middle East and Africa. 

Growing prevalence to improve healthcare infrastructures across the region is mainly propelling the demand of the market. The rise in the incidences of life-threatening diseases is also elevating the demand of the market. In addition, the rising number of cancer patients in the world coupled with innovation in liquid biopsy technology is anticipated to drive the global liquid biopsy market over the forecast period.

However, expensive medical procedures & a cost-intensive research process involved in the liquid biopsy are anticipated to restrain the development of the global liquid biopsy market over the next few years. In addition, the liquid biopsy required a skilled workforce, which is difficult to get. Lack of proper awareness over the availability of different treatment procedures is hindering the growth of the market. Unfavorable government policies are also impeding the demand of the MEA in-vitro diagnostics market.

This research report on the North American Liquid Biopsy Market has been segmented and sub-segmented market into the following categories:

By Cancer Type: 

  • Lung Cancer
  • Pancreatic Cancer
  • Leukemia
  • Other Visceral Cancers

By Diagnostic Approach: 

  • Circulating Tumour cells (CTC)
  • Circulating Tumour DNA (ctDNA)
  • RNA in exosomes
  • Extra-Cellular Vesicles

By End-Users: 

  • Reference Laboratories
  • Hospital/Physician Laboratories
  • Academic and Research Centers
  • Other End Users

By Country: 

  • UK
  • France
  • Spain
  • Germany
  • Italy
  • Russia
  • Sweden
  • Denmark
  • Switzerland
  • Netherlands
  • Turkey
  • Czech Republic
  • Rest of Europe

Regionally, UAE has the highest market share in the Middle East. The government is investing in the research and development of innovative products that solely fuel the market demand. Many institutes in this region are researching the liquid biopsy technique. The emergence of the latest techniques and promoting quality services in healthcare are enhancing the market's demand. 


A few of the promising companies operating in the MEA Liquid Biopsy Market are Janssen Diagnostics, Qiagen, Rarecells SAS, Silicon Biosystems, SRI International, Myriad Genetics, Natera, Personal Genome Diagnostics, Sysmex Inostics, Trovagene, Exosome Diagnostics, Exosome Sciences, and HansaBiomed OU.

1. Introduction                                                                 

                1.1 Market Definition                                                    

                1.2 Study Deliverables                                                  

                1.3 Base Currency, Base Year and Forecast Periods                                                           

                1.4 General Study Assumptions                                                

2. Research Methodology                                                                           

                2.1 Introduction                                                              

                2.2 Research Phases                                                      

                                2.2.1 Secondary Research                                            

                                2.2.2 Primary Research                                 

                                2.2.3 Econometric Modelling                                     

                                2.2.4 Expert Validation                                  

                2.3 Analysis Design                                                         

                2.4 Study Timeline                                                          

3. Overview                                                                      

                3.1 Executive Summary                                                

                3.2 Key Inferences                                                         

                3.3 New Developments                                                

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                                                      

                4.1 Market Drivers                                                          

                4.2 Market Restraints                                                    

                4.3 Key Challenges                                                         

                4.4 Current Opportunities in the Market                                               

5. Market Segmentation                                                                              

                5.1 By Cancer Type                                                         

                                5.1.1 Lung Cancer                                           

                                5.1.2 Pancreatic Cancer                                

                                5.1.3 Leukemia                                

                                5.1.4 Other Visceral Cancers                                       

                5.2 By Sample Type                                                        

                                5.2.1 Blood                                        

                                5.2.2 Urine                                         

                                5.2.3 Plasma                                      

                                5.2.4 Saliva                                         

                                5.2.5 Cerebrospinal                                        

                5.3 By Diagnostic Approach                                                        

                                5.3.1 Circulating Tumour cells (CTC)                                        

                                5.3.2 Circulating Tumour DNA (ctDNA)                                  

                                5.3.3 RNA in exosomes                                 

                                5.3.4 Extra-Cellular Vesicles                                        

                5.4 By End Users                                                             

                                5.4.1 Reference Laboratories                                     

                                5.4.2 Hospital/Physician Laboratories                                     

                                5.4.3 Academic and Research Centers                                    

                                5.4.4 Other End Users                                   

6. Geographical Analysis                                                                              

                6.1 Introduction                                                              

                6.2 Middle-East                                                                

                6.3 Africa                                                            

7. Strategic Analysis                                                                       

                7.1 PESTLE analysis                                                         

                                7.1.1 Political                                     

                                7.1.2 Economic                                 

                                7.1.3 Social                                         

                                7.1.4 Technological                                         

                                7.1.5 Legal                                          

                                7.1.6 Environmental                                      

                7.2 Porter’s Five analysis                                                              

                                7.2.1 Bargaining Power of Suppliers                                        

                                7.2.2 Bargaining Power of Consumers                                    

                                7.2.3 Threat of New Entrants                                     

                                7.2.4 Threat of Substitute Products and Services                               

                                7.2.5 Competitive Rivalry within the Industry                                      

8. Market Leaders' Analysis                                                                        

                8.1 Janssen Diagnostics                                                

                                8.1.1 Overview                                

                                8.1.2 Product Analysis                                   

                                8.1.3 Strategic Evaluation and Operations                                            

                                8.1.4 Financial analysis                                  

                                8.1.5 Legal issues                                            

                                8.1.6 Recent Developments                                       

                                8.1.7 SWOT analysis                                       

                                8.1.8 Analyst View                                          

                8.2 Qiagen                                                         

                8.3 Rarecells SAS                                                             

                8.4 Silicon Biosystems                                                   

                8.5 SRI International                                                      

                8.6 Myriad Genetics                                                      

                8.7 Natera                                                          

                8.8 Personal Genome Diagnostics                                                            

                8.9 Sysmex Inostics                                                        

                8.10 Trovagene                                                

                8.11 Exosome Diagnostics                                                           

                8.12 HansaBiomed OU                                                  

9. Competitive Landscape                                                                           

                9.1 Market share analysis                                                            

                9.2 Merger and Acquisition Analysis                                                        

                9.3 Agreements, collaborations and Joint Ventures                                                          

                9.4 New Product Launches                                                          

10. Expert Opinions                                                                        

                10.1 Market Outlook                                                     

                10.2 Investment Opportunities                                                 


                a) List of Tables                                                

                b) List of Figures                                                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Middle East & Africa Liquid Biopsy Market, By Region, From 2021 to 2026 (USD Billion)
  2. Middle East & Africa Liquid Biopsy Market, By Cancer Type, From 2021 to 2026 (USD Billion)
  3. Middle East & Africa Lung Cancer Market, By Region, From 2021 to 2026 (USD Billion)
  4. Middle East & Africa Pancreatic Cancer Market, By Region, From 2021 to 2026 (USD Billion)
  5. Middle East & Africa Leukemia Market, By Region, From 2021 to 2026 (USD Billion)
  6. Middle East & Africa Other Visceral Cancers Market, By Region, From 2021 to 2026 (USD Billion)
  7. Middle East & Africa Liquid Biopsy Market, By Sample Type, From 2021 to 2026 (USD Billion)
  8. Middle East & Africa Blood Market, By Region, From 2021 to 2026 (USD Billion)
  9. Middle East & Africa Urine Market, By Region, From 2021 to 2026 (USD Billion)
  10. Middle East & Africa Plasma Market, By Region, From 2021 to 2026 (USD Billion)
  11. Middle East & Africa Saliva Market, By Region, From 2021 to 2026 (USD Billion)
  12. Middle East & Africa Cerebrospinal Market, By Region, From 2021 to 2026 (USD Billion)
  13. Middle East & Africa Liquid Biopsy Market, By Diagnostic Approach, From 2021 to 2026 (USD Billion)
  14. Middle East & Africa Circulating Tumour cells (CTC) Market, By Region, From 2021 to 2026 (USD Billion)
  15. Middle East & Africa Circulating Tumour DNA (ctDNA) Market, By Region, From 2021 to 2026 (USD Billion)
  16. Middle East & Africa RNA in exosomes Market, By Region, From 2021 to 2026 (USD Billion)
  17. Middle East & Africa Extra-Cellular Vesicles Market, By Region, From 2021 to 2026 (USD Billion)
  18. Middle East & Africa Liquid Biopsy Market, By End Users, From 2021 to 2026 (USD Billion)
  19. Middle East & Africa Reference Laboratories Market, By Region, From 2021 to 2026 (USD Billion)
  20. Middle East & Africa Hospital/Physician Laboratories Market, By Region, From 2021 to 2026 (USD Billion)
  21. Middle East & Africa Academic and Research Centers Market, By Region, From 2021 to 2026 (USD Billion)
  22. Middle East & Africa Other End Users Market, By Region, From 2021 to 2026 (USD Billion)
  23. Middle East Liquid Biopsy Market, By Cancer Type, From 2021 to 2026 (USD Billion)
  24. Middle East Liquid Biopsy Market, By Sample Type, From 2021 to 2026 (USD Billion)
  25. Middle East Liquid Biopsy Market, By Diagnostic Approach, From 2021 to 2026 (USD Billion)
  26. Middle East Liquid Biopsy Market, By End Users, From 2021 to 2026 (USD Billion)
  27. Africa Liquid Biopsy Market, By Cancer Type, From 2021 to 2026 (USD Billion)
  28. Africa Liquid Biopsy Market, By Sample Type, From 2021 to 2026 (USD Billion)
  29. Africa Liquid Biopsy Market, By Diagnostic Approach, From 2021 to 2026 (USD Billion)
  30. Africa Liquid Biopsy Market, By End Users, From 2021 to 2026 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports


$ 1234 2875

Click for Request Sample